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Nonalcoholic steatosis (fatty liver) is a major cause of
liver dysfunction that is associated with insulin resis-
tance and metabolic syndrome. The cJun NH2-
terminal kinase 1 (JNK1) signaling pathway is impli-
cated in the pathogenesis of hepatic steatosis and
drugs that target JNK1 may be useful for treatment
of this disease. Indeed, mice with defects in JNK1
expression in adipose tissue are protected against
hepatic steatosis. Here we report that mice with
specific ablation of Jnk1 in hepatocytes exhibit
glucose intolerance, insulin resistance, and hepatic
steatosis. JNK1 therefore serves opposing actions
in liver and adipose tissue to both promote and
prevent hepatic steatosis. This finding has potential
implications for the design of JNK1-selective drugs
for the treatment of metabolic syndrome.
INTRODUCTION
Nonalcoholic fatty liver disease is the leading cause of liver
dysfunction in the non-alcoholic, viral hepatitis-negative, popu-
lation in the USA and Europe (Angulo and Lindor, 2002; Cor-
tez-Pinto et al., 2006; Skelly et al., 2001). The disease represents
a spectrum of liver pathologies, including steatosis, nonalcoholic
steatohepatitis, and nonalcoholic cirrhosis. The incidence of
nonalcoholic fatty liver disease is associated with obesity, dysli-
pidemia, insulin resistance, and type 2 diabetes (Anstee and
Goldin, 2006). It is likely that this disease represents one aspect
of metabolic syndrome (Marchesini et al., 2003; Sanyal, 2002).
The cJun NH2-terminal kinase 1 (JNK1) signaling pathway is
implicated in the pathogenesis of metabolic syndrome (Weston
and Davis, 2007). Thus, inhibitory phosphorylation of the adaptor
protein IRS1 by JNK1 can cause insulin resistance (Aguirre et al.,
2000). Indeed, Jnk1/ mice are protected against insulin resis-
tance caused by feeding a high-fat diet (HFD) (Hirosumi et al.,
2002). This observation implicates JNK1 in the regulation of
insulin resistance in vivo. However, Jnk1/ mice exhibit resis-
tance to HFD-induced obesity (Hirosumi et al., 2002). It is there-
fore possible that the effects of JNK1 deficiency on insulin resis-Celltance in vivo are a consequence of the failure of HFD-fed Jnk1/
mice to develop obesity. Nevertheless, direct evidence demon-
strating a role for JNK1 in the regulation of insulin resistance has
been obtained from studies of mice with adipose-specific JNK1
deficiency that exhibit protection against HFD-induced insulin
resistance and hepatic steatosis despite normal development
of HFD-induced obesity (Sabio et al., 2008).
The liver represents a site of metabolic regulation by JNK1.
Indeed, studies using adenoviral delivery of dominant-negative
JNK (Nakatani et al., 2004) or Jnk shRNA (Yang et al., 2007) to
the liver indicate that JNK1 plays an important role in negative
regulation of hepatic insulin signaling. Furthermore, Jnk1/
mice fed a methione and choline-deficient diet are less suscep-
tible to hepatic steatosis (Schattenberg et al., 2006). Moreover,
transgenic expression of the MAP kinase phosphatase DUSP-9
in the liver suppresses the activation of MAP kinases, including
JNK, and increases insulin sensitivity (Emanuelli et al., 2008).
Together, these data indicate that JNK1 plays a critical role in
metabolic regulation of the liver. However, it is established that
hepatic function, including steatosis and insulin resistance, can
be regulated by JNK1 in adipose tissue (Sabio et al., 2008).
The relative contribution of JNK1 in hepatocytes to the regulation
of HFD-induced hepatic insulin resistance and steatosis is there-
fore unclear.
The purpose of this study was to test the role of hepatic JNK1.
Our approach was to examine the effect of hepatocyte-specific
ablation of the Jnk1 gene in mice. Contrary to expectations, we
found that these mice exhibit glucose intolerance, insulin resis-
tance, and hepatic steatosis.
RESULTS AND DISCUSSION
To test the role of JNK1 in the liver, we createdmicewithout (LWT)
and with (LKO) selective ablation of the Jnk1 gene in hepatocytes
(Figure 1A). Loss of hepatic JNK1 did not alter the expression of
other JNK isoforms (Figure S1). Measurement of JNK activity
demonstrated that a high-fat diet (HFD) caused JNK activation
in the liver and adipose tissue of control (LWT) mice, but JNK acti-
vation was detected only in adipose tissue and not in liver of LKO
mice (Figure 1B). A JNK substrate site (Ser307) that negatively
regulates insulin receptor substrate (IRS)-1 (Aguirre et al., 2000)
exhibited increased phosphorylation in the liver of HFD-fed LWT
mice, but not in LKO mice (Figure 1C). Together, these dataMetabolism 10, 491–498, December 2, 2009 ª2009 Elsevier Inc. 491
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Role of JNK1 in LiverFigure 1. Mice with Hepatocyte-Specific Deficiency of JNK1 Are Glucose Intolerant
(A) The liver and quadricepsmuscle ofAlb-cre Jnk1+/+ (LWT) mice,Alb-cre Jnk1LoxP/LoxP (LKO) mice, and Jnk1/ (KO)micewere examined by immunoblot analysis
by probing with antibodies to JNK1 and GAPDH.
(B) LWT and LKOmice were fed a chow diet (ND) or a high fat diet (HFD) for 16 wks. JNK activity in epididymal (white) fat and liver wasmeasured in a protein kinase
(KA) assay using cJun and ATP[g-32P] as substrates. The cell extracts used for the protein kinase assay were also examined by immunoblot analysis by probing
with an antibody to GAPDH.
(C) The phosphorylation of IRS1 on Ser-307 in the liver was examined using ND- and HFD- fed LWT and LKO mice by immunoblot analysis by probing with anti-
bodies to IRS1 and phosphoSer-307 IRS1.
(D) Chow- fed LWT and LKO mice were fasted overnight and administered glucose (2g/kg) by intraperitoneal injection. The activation of AKT in the liver was exam-
ined by immunoblot analysis by probing with antibodies to AKT and phosphoAKT.
(E) Glucose tolerance tests of chow-fed LWT and LKO mice were performed by measurement of blood glucose concentration in animals following intraperitoneal
injection of glucose (1g/kg). The data presented represent the mean ± SD (n = 10 15). Statistically significant differences are indicated (*p < 0.05; **p < 0.01).
(F) Chow- fed LWT and LKOmice were fasted overnight or fed ad libitum and the blood glucose concentration wasmeasured (mean ± SD; n = 1015). Statistically
significant differences are indicated (***p < 0.001).indicate that mice with hepatocyte-specific JNK1 deficiency
represent a model for the analysis of the role of JNK1 in the liver.
Hepatocyte-Specific JNK1 Deficiency Causes Glucose
Intolerance
We anticipated that LKO mice would exhibit protection against
the deleterious effects of diet-induced obesity compared with
LWT mice. This expectation was based on previous studies that
have established a role for JNK1 as an inhibitor of insulin signal
transduction in multiple tissues (Aguirre et al., 2000; Hirosumi
et al., 2002; Sabio et al., 2008). Moreover, studies using intrave-
nous administration of adenovirus vectors to interfere with the
JNK1 pathway in the liver suggest that hepatic JNK1 negatively
regulates insulin signaling in the liver (Nakatani et al., 2004; Yang
et al., 2007). In contrast, we found that HFD-fed LKO and LWT
mice exhibited similar glucose intolerance (Figure S2A), insulin-492 Cell Metabolism 10, 491–498, December 2, 2009 ª2009 Elsevieinduced decrease in blood glucose levels (Figure S2B),
glucose-induced insulin release (Figure S2C), and serum
glucose levels (Figures S3B and S3C). Furthermore, hyperinsuli-
nemic-euglycemic clamp studies demonstrated a similar loss of
hepatic insulin action in HFD-fed LKO and LWT mice (Figure S3F).
These data indicated that JNK1 deficiency in hepatocytes does
not protect against diet-induced insulin resistance. Moreover,
we found that chow-fed LKO mice exhibited a profound defect
in glucose-induced activation of hepatic AKT (Figure 1D), glu-
cose intolerance (Figure 1E), andmild hyperglycemia (Figure 1F).
The observation that mice with hepatocyte-specific ablation of
the Jnk1 gene exhibit glucose intolerance (Figure 1E) contrasts
with conclusions of previous studies of hepatic JNK1 that have
employed intravenous delivery of adenoviruses that express
dominant-negative JNK (Nakatani et al., 2004) or Jnk shRNA
(Yang et al., 2007). The mechanism that accounts for ther Inc.
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Role of JNK1 in Liverdifferent phenotypes of these mouse models is unclear. One
possibility is that these phenotypes reflect the effect of disrup-
tion of the JNK1 signaling pathway in different cell types. Thus,
Cre-mediated ablation of Jnk1 in hepatocytes may differ from
the effect of adenovirus-mediated suppression of JNK1
signaling in multiple hepatic cell types, including hepatocytes,
stellate cells, endothelial cells, and innate immune cells (e.g.,
Kupffer cells and NKT cells). Indeed, studies of murine hepatitis
have established that the phenotype of mice with hepatocyte-
specific ablation of Jnk1markedly differs frommice with ablation
of Jnk1 in multiple hepatic cell types (Das et al., 2009).
Hepatocyte-Specific JNK1 Deficiency Increases
Insulin Clearance
The major defect in glucose-induced hepatic insulin signaling
observed in chow-fedLKOmice (Figure1D)may reflect a reduction
in the blood concentration of insulin. No significant difference in
the fasting blood insulin concentration between LKO and LWT
mice was detected (Figure 2A). Morphological analysis demon-
strated that the size of pancreatic islets was similar in LKO and
LWT mice (Figure S4). Nevertheless, the amount of glucose-
induced blood insulin was markedly decreased in LKO mice
compared with LWT mice (Figure 2B). This loss of blood insulin
could result from decreased insulin secretion or increased insulin
clearance. To distinguish between these possible mechanisms,
we examined the blood concentration of C-peptide (a proteolytic
by-product of insulin processing) that is secreted together with
insulin frompancreaticbcells.We found that the fastingC-peptide
concentration in the blood of LKO mice was greatly increased
compared with LWT mice (Figure 2C). Nevertheless, a similar
glucose-induced increase in blood C-peptide concentration was
detected in LKO and LWT mice (Figure 2D), suggesting that insulin
secretion was not altered in LKO mice. Together, these observa-
tions suggest that insulin clearance was increased in LKO mice
compared with LWT mice. To test this hypothesis, we injected
micewithhuman insulin andmeasured the timecourseofchanges
in the concentration of human insulin in the blood. This analysis
demonstrated that, compared with LWT mice, the peak insulin
concentration detected in LKO mice was greatly reduced
(Figure 2E). The clearance of blood insulin by LKO mice was also
markedly increased compared with LWT mice (Figure 2E).
Together, thesedata indicate that thenormal levelsofblood insulin
detected in fasting LKOmiceare due to increased insulin clearance
balanced by a compensatory increase in insulin secretion.
The liver is the major site of insulin clearance within the body.
Indeed, it is estimated that 50% of insulin newly secreted by
pancreatic b cells into the portal vein is internalized and
degraded by the liver (Duckworth et al., 1998). Hepatic insulin
clearance requires the insulin receptor (Michael et al., 2000)
and is regulated by Ceacam1 (Poy et al., 2002). The increased
amounts of insulin receptor and Ceacam1 in the liver (Figures
2F and S5) may contribute to the increased insulin clearance in
LKO mice (Figure 2E).
Hepatocyte-Specific JNK1 Deficiency Causes Insulin
Resistance
To further characterize the metabolic phenotype of chow-fed
LKO mice, we performed a hyperinsulinemic-euglycemic clamp
study. This analysis demonstrated that LKO mice exhibitedCell Mincreased hepatic glucose production (HGP) during the clamp
and therefore decreased hepatic insulin action compared with
LWT mice (Figures 3B and 3C). Indeed, the liver of LKO mice ex-
pressed increased amounts of PGC-1a (Figure S6), a coactivator
of the gluconeogenic gene transcription factors HNF4a and
FOXO1 (Puigserver et al., 2003; Yoon et al., 2001). Basal HGP
and insulin-stimulated whole-body glucose turnover were not
altered in LKO mice (Figures 3A and 3D). The fat and lean mass
of LWT and LKO mice were similar (Figures 3E and 3F). Insulin
treatment caused similar JNK-independent (Rui et al., 2001)
negative feedback phosphorylation of IRS1 on Ser307 in LKO
mice compared with LWT mice (Figure 3I). However, decreased
hepatic AKT activation was detected in LKO mice compared
with LWT mice (Figures 3G and 3H). This reduction in AKT activa-
tion was associated with reduced insulin-stimulated tyrosine
phosphorylation of the insulin receptor and IRS1 (Figure S7).
Together, these data demonstrate that hepatic loss of JNK1
causes insulin resistance in liver.
Hepatocyte-Specific JNK1 Deficiency Causes
Hepatic Steatosis
The increased insulin clearance and hepatic insulin resistance
phenotypeofchow-fedLKOmicecomparedwithLWTmice (Figures
2 and 3) is likely to cause profound metabolic consequences.
Indeed, we found that chow-fed LKO mice exhibited hepatic
steatosis (Figure 4A) associated with increased accumulation of
triglyceride (Figure 4B) and increased inflammation (Figure S8)
compared with LWT mice. Increased amounts of triglyceride were
also detected in the blood of chow-fed LKO mice (Figure S9). In
contrast,HFD-fedLKOandLWTmiceaccumulatedasimilar amount
of triglyceride in liver (Figure S10).
The increased triglyceride accumulation in chow-fed LKO mice
could be mediated by increased dietary lipid absorption,
decreased fat oxidation, and/or increased lipogenesis.We found
no differences between LKO and LWT mice in the respiratory
exchange quotient [VCO2]/[VO2] (Figure S11) or the intestinal
absorption of dietary fat (Figure S12). The LKO mice exhibited
increased energy expenditure compared with LWT mice, but no
differences in food/water intake or physical activity in LKO mice
were detected (Figure S11). These observations do not support
a role for increased dietary fat absorption or decreased fat
oxidation as a cause of the hepatic steatosis in LKO mice. De
novo lipogenesis may therefore contribute to steatosis in LKO
mice. Indeed, increased lipogenesis was detected in the liver of
chow-fed LKO mice compared with LWT mice (Figure 4C). More-
over, LKO liver exhibited increased expression of genes that
promote hepatic lipogenesis (C/ebpa, C/ebpb, Pgc-1b, Pparg,
and Srebp1) and also genes that encode enzymes that con-
tribute to lipogenesis (Acaca/b, Acot3, Acsl1/4, Dgat1, Fas, and
Gyk) and the export of triglyceride from the liver (Mttp) (Figure 4E).
Thesechanges ingeneexpressioncontribute tohepatic steatosis
in chow-fed LKOmice compared with LWTmice. Furthermore, the
increased expression of C/ebpb in the liver of LKO mice may
contribute to enhanced insulin clearance by increasing insulin
receptor expression (Foti et al., 2003) (Figures 2E and 2F).
Implications
Steatosis is a widespread human disease that can progress to
steatohepatitis and liver failure (Angulo and Lindor, 2002;etabolism 10, 491–498, December 2, 2009 ª2009 Elsevier Inc. 493
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Role of JNK1 in LiverFigure 2. JNK1 Deficiency in Hepatocytes Increases Insulin Clearance
(A) Chow-fed LWT and LKO mice were fasted overnight. In (A), the concentration of blood insulin was measured (mean ± SD; n = 10). No statistically significant
difference between LKO and LWT mice was detected.
(B) The effect of administration of glucose (2 g/kg body mass) by intraperitoneal injection on blood insulin concentration was examined (mean ± SD; n =13–15).
Statistically significant differences between LKO and LWT are indicated (*p < 0.01).
(C) The concentration of insulin C-peptide in the blood was measured (mean ± SD; n = 10–15). Statistically significant differences between LKO and LWT are
indicated (****p < 0.0001).
(D) The effect of administration of glucose (2 g/kg body mass) on insulin C-peptide concentration in the blood was examined (mean ± SD; n = 15). No statistically
significant difference between LKO and LWT was detected.
(E) Mice were injected with human insulin (1.5 U/kg body mass). The concentration of human insulin in the blood was measured (mean ± SD; n = 15). Statistically
significant differences between LKO and LWT are indicated (*p < 0.05).
(F) The expression of the insulin receptor, Ceacam-1, and Gapdh mRNA in the liver was measured by quantitative RT-PCR (Taqman) assays. The expression of
insulin receptor (InsR) and Caecam-1 mRNA was normalized to the amount of 18S RNA in each sample (mean ± SD; n = 7). Statistically significant differences
between LKO and LWT are indicated (*p < 0.05; ***p < 0.001).Cortez-Pinto et al., 2006; Skelly et al., 2001). The finding that the
loss of JNK1 in hepatocytes causes steatosis identifies
a possible complication of drug therapies involving JNK1 inhibi-
tion designed to treat insulin resistance. Indeed, the hepatic494 Cell Metabolism 10, 491–498, December 2, 2009 ª2009 Elsevierinsulin resistance caused by hepatocyte-specific ablation of
the Jnk1 gene is associated with increased gluconeogenesis
and also increased lipogenesis. This paradox (selective insulin
resistance) represents a central characteristic of type 2 diabetesInc.
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Role of JNK1 in LiverFigure 3. Mice with JNK1-Deficient Hepatocytes Exhibit Hepatic Insulin Resistance
(A–F) Insulin sensitivity wasmeasured using a hyperinsulinemic-euglycemic clamp in conscious chow-fed LKO and LWTmice. In (A), basal hepatic glucose produc-
tion (HGP) is shown. In (B), insulin-stimulated rate of HGP is shown. In (C), hepatic insulin action, expressed as insulin-mediated percent suppression of basal
HGP is portrayed. In (D), insulin-stimulated whole body glucose turnover is shown. In (E), whole-body fat mass measured using 1H-MRS is shown. In (F), whole-
body lean mass is shown. The data presented are the mean ± SE for 6–8 experiments. Statistically significant differences between LKO mice and LWT mice are
indicated (*p < 0.05).
(G and H) Chow-fed LKO and LWT mice were administered insulin (0.3U/kg body mass) by intravenous injection (5 min). The activation of AKT in the liver was
examined by immunoblot analysis by probing with antibodies to AKT and phospho-AKT. The relative amount of phospho-AKT is presented as the mean ±
SD (n = 3). Statistically significant differences between LKO and LWT mice are indicated (*p < 0.05).
(I) Chow-fed LKO and LWT mice were administered insulin (0.3U/kg body mass) by intravenous injection (5 min). The phosphorylation of IRS1 on Ser307 in the liver
was examined by immunoblot analysis by probing with antibodies to IRS1 and phospho-Ser307 IRS1.with suppression of the FOXO1 pathway and activation of the
SREBP-1 pathway (Brown and Goldstein, 2008). These consid-
erations indicate that hepatocyte-specific JNK1-deficient miceCell Mexhibit the typical features of insulin resistance that are associ-
ated with metabolic syndrome. The increased expression of
the transcription factor FOXO1, the coactivator PGC-1a, andetabolism 10, 491–498, December 2, 2009 ª2009 Elsevier Inc. 495
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Role of JNK1 in LiverFigure 4. JNK1 Deficiency in Hepatocytes Causes Steatosis
(A) Chow-fed LWT and LKO mice were fasted overnight. Representative sections of the liver stained with oil red O are presented.
(B) The amount of hepatic triglyceride was measured in mice fasted overnight (mean ± SD; n = 10). Statistically significant differences between LKO and LWT are
indicated (*p < 0.05).
(C) The amount of hepatic lipogenesis was measured in mice fasted 6 hr (mean ± SD; n = 8–9). Statistically significant differences between LKO and LWT are
indicated (*p < 0.05).
(D) The expression of genes that encode lipogenic transcription factors and coactivators in the liver of chow-fed LKO and LWT mice that were fasted overnight
(C/ebpa, C/ebpb, Pgc1b, Pparg, and Srebp1) was measured by quantitative RT-PCR assays of the amount of mRNA and was normalized to the amount of
18S RNA in each sample (mean ± SD; n = 7). Statistically significant differences between LKO and LWT are indicated (*p < 0.05; **p < 0.01).
(E) The expression of genes that encode enzymes that promote lipogenesis in the liver of chow-fed LKO and LWT mice that were fasted overnight (Fas, fatty acid
synthase; Acsl1/4, acetyl-CoA synthetase long chain family member 1/4; Acaca/b, acetyl-CoA carboxylase a/b; Acot3, Acetyl-CoA thioesterase; Dgat1,
Diacylglycerol O-acyltransferase homolog 1; Glyk, Glycerol kinase; Mttp, microsomal triglyceride transfer protein) was measured by quantitative RT-PCR assays
of the amount of mRNA and was normalized to the amount of 18S RNA in each sample (mean ± SD; n = 7). Statistically significant differences between LKO and
LWT are indicated (*p < 0.05; **p < 0.01).gluconeogenic target genes (e.g., Pepck) may contribute to
gluconeogenesis in LKO mice (Figure S6). The mechanism that
accounts for increased lipogenesis is unclear, but it is most likely
the result of increased expression of multiple lipogenic genes
(Figure 4E) and increased expression of lipogenic transcription
factors (e.g., SREBP-1, C/EBPa/b, and PPARg) and the coacti-
vator PGC-1b (Figure 4D).
Hepatic steatosis is prevented in Jnk1/ mice (Schattenberg
et al., 2006). This observation suggests that the metabolic milieu
in response to JNK1 deficiency in different organs may compen-
sate for the effects of JNK1 deficiency in hepatocytes. Indeed,
JNK1 plays a major regulatory role in adipose tissue leading to
protection against HFD-induced hepatic insulin resistance and
steatosis (Sabio et al., 2008). This is consistent with the finding
that systemic treatment of mice with a JNK inhibitor can protect
against the effects of feeding a HFD (Kaneto et al., 2004).
However, not all of the deleterious effects of hepatocyte-specific
JNK1 deficiency are compensated in Jnk1/ mice, including
increased insulin clearance (Figure S13).496 Cell Metabolism 10, 491–498, December 2, 2009 ª2009 ElseviThe observation that hepatic JNK1 deficiency increases
insulin clearance has implications for the use of JNK1 as
a drug target for the treatment of metabolic syndrome, including
insulin resistance and steatosis. Disease progression frommeta-
bolic syndrome to type 2 diabetes is triggered by the failure of
pancreatic b cells due to exhaustion (Burks and White, 2001).
In this regard, the compensatory increase in insulin secretion in
response to enhanced insulin clearance caused by hepatic
JNK1 inhibition may have adverse chronic effects on b cell func-
tion. The cytoprotective effects of JNK inhibition on b cells
(Bonny et al., 2001) may therefore be critical for the design of
effective therapies that target JNK1 for the treatment of meta-
bolic syndrome.
EXPERIMENTAL PROCEDURES
Mice
We have described Jnk1/ mice (Dong et al., 1998), Jnk1f/f mice (Das et al.,
2007), and Jnk2/ mice (Yang et al., 1998). Alb-Cre mice (Postic et al.,er Inc.
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Role of JNK1 in Liver1999) were obtained from Jackson Laboratory. The mice were backcrossed to
the C57BL/6J strain (Jackson Laboratory) and were housed in facilities
accredited by the American Association for Laboratory Animal Care (AALAC).
All studies were performed using male mice (8–24 weeks old). The mice
were genotyped by PCR analysis of genomic DNA (Das et al., 2007).
The animal studies were approved by the Institutional Animal Care and
Use Committees (IACUC) of the University of Massachusetts Medical School,
University of Cincinnati, and Pennsylvania State University College of
Medicine.
Immunoblot Analysis
Tissue extracts were prepared using Triton lysis buffer (20 mM Tris [pH 7.4],
1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM b-glycer-
ophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluo-
ride, and 10 mg/mL of aprotinin and leupeptin). Extracts (20–50 mg of protein)
and immunoprecipitates (prepared from 2–10 mg protein) were examined by
protein immunoblot analysis. The antibodies employed were the following:
AKT, phosphoSer-308 AKT, and phosphoSer-473 AKT (Cell Signaling); IRS1
(Sabio et al., 2008); IRS2, phosphotyrosine, and phospho-Ser307 IRS1 (Milli-
pore); insulin receptor b subunit, JNK1 and GAPDH (Santa Cruz); and JNK1/
2 (BD PharMingen). Immunecomplexes were detected by enhanced chemilu-
minescence (NEN). Quantitation of immunoblots was performed using the
Odyssey infrared imaging system (LI-COR Biosciences).
Measurement of Blood Glucose and Insulin Concentration
Blood glucose was measured with an Ascensia Breeze 2 glucose meter
(Bayer). Insulin and insulin C-peptide in plasmaweremeasured by ELISA using
a Luminex 200 machine (Millipore).
Statistical Analysis
Differences between groups were examined for statistical significance using
the Student’s test or analysis of variance (ANOVA) with the Fisher’s test.
SUPPLEMENTAL DATA
The Supplemental Data include 13 figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at http://www.cell.com/cellmetabolism/supplemental/S1550-4131(09)
00295-2.
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